Harnessing AI in Pharmacovigilance: Using Technology as an Enabler Across the Clinical Development – Post-Marketing Continuum

Artificial intelligence (AI) is rapidly transforming how life sciences organizations approach pharmacovigilance. From clinical development to post-marketing surveillance, AI-driven technologies such as natural language processing, predictive analytics, and machine learning are enabling smarter, faster, and more efficient safety operations.

Agenda:

• Understanding current trends in AI across the drug development continuum

• Challenges of managing PV data volume and complexity

• Leveraging AI to optimize post-market safety monitoring

• Future opportunities for AI in safety and regulatory compliance

• Q & A